English
Our goal is to inclusively partner with all healthcare stakeholders to help change the standards of care and cancer management.
MiRNA Scientific is developing products and services which may revolutionize the standards of care supporting urologic oncology, including prostate, bladder and kidney cancers. Such new standards are urgently needed given the prevalence of these cancers and their debilitating burden globally.
MiRNA Scientific proudly presents our initial product: the miR Sentinel Prostate Cancer Test, a non-invasive liquid biopsy urine test that detects, classifies and can monitor prostate cancer at the molecular level. MiRNA Scientific is a majority-owned operating subsidiary of Huminn LLC (formerly known as Impact NRS) and is headquartered in New York City with operating subsidiaries in Israel.
The miR Sentinel Prostate Cancer Test is a liquid biopsy urine test that uses molecular information to categorize patients into one of three groups: No Molecular Evidence of Prostate Cancer, Low Risk for Aggressive Prostate Cancer, or Elevated Risk for Aggressive Prostate Cancer, thereby delivering clear, accurate and actionable results for providers and their patients alike, answering the two most important questions: Is there molecular evidence of prostate cancer? If so, how severe is the risk of aggressive disease?
With comprehensive molecular insight into the prostate gland, a single test both detects the presence or absence of prostate cancer and classifies it by risk profile, giving miR Sentinel the power to outperform an array of prostate cancer diagnostic procedures.
With data showing high sensitivity for all prostate cancers, including GG≥2, and subset analyses showing that many patients with false-negative biopsies are correctly identified with molecular evidence of aggressive prostate cancer, provide a clear rationale for adopting the miR Sentinel Prostate Test. This test is in a class of its own and should be implemented to better stratify at-risk patients.
We anticipate opening new clinical studies in the near future.If you are interested in being notified once a study is opened, please use the Contact Us link
.png)